June 6, 2013
/PRNewswire/ -- MRI Interventions, Inc. (OTCQB: MRIC) announced today that its Chief Executive Officer,
, will deliver a presentation at the Brain Tumor Biotech Summit 2013 regarding the application of the company's ClearPoint® Neuro Intervention System as a platform for MRI-guided drug delivery in treatment of brain tumors. Jenkins' talk titled "ClearPoint Technologies for MRI-Guided Therapies" will take place
June 7, 2013
during the session "Imaging Applications and Treatment for Malignant Glioma."
MRI Interventions' ClearPoint system enables real-time MRI-guided navigation for a wide range of minimally-invasive neurosurgery procedures, and the platform is particularly well-suited for facilitating drug delivery directly to brain tumors. Some historical challenges with drug delivery to the brain – bypassing the blood brain barrier, side effects associated with systemic delivery, inability to see the placement of the drug delivery cannula and difficulty confirming tumor coverage – are addressed through the direct visualization and precise device placement that the ClearPoint system enables.
The ClearPoint platform's integrated system of reusable components, disposable components and intuitive menu-driven software is designed to provide real-time visual guidance for the placement and operation of instruments during neurological procedures performed within the MRI environment. A surgeon using the ClearPoint system for direct drug delivery to a brain tumor first sees and selects the target location, aims the ClearPoint targeting device and watches via MR-imaging as the drug delivery cannula is advanced to the target location inside the patient's brain. The surgeon can then visually monitor the flow and administration of the drug at the point of delivery.
The ClearPoint system is currently involved in five different clinical trials to enable delivery of investigational therapeutics, three of which are for brain tumors and two of which are for Parkinson's disease.